Article
A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations…
bioRxiv · 2021 · Lorena M. Coria
Key facts
| Title | A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection |
|---|---|
| First author | Lorena M. Coria |
| Journal | bioRxiv |
| Published | Dec 9, 2021 |
| DOI | 10.1101/2021.12.07.471590 |
| Devices mentioned | 070667 |
| Product codes mentioned | MVU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1